M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition PharmaphorumIpsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.HematologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) Pharmaphorum Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Jaypirca receives CHMP positive opinion for CLL in EuropeNext: Viridian wins FDA approval for Lumvoa for thyroid eye disease Related Stories M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover pharminent July 16, 2026
